Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
An employee shareholder of EQ has filed a notice of proposed sale on Form 144 to sell 6,533 shares of common stock. The shares are to be sold through Maxim Group, with an aggregate market value of $8,427.00, on the NASDAQ, with an approximate sale date of 01/08/2026. These shares were acquired on 06/18/2024 under an Employee Stock Purchase Plan from the issuer and were paid for in cash on 12/12/2025. The company had 60,893,283 shares of common stock outstanding at the time referenced in the notice.
Equillium’s Senior Vice President and Chief Operating Officer reported open-market sales of company common stock. On December 12, 2025, the executive sold 23,804 shares of Equillium common stock at a price of $1.34 per share. On December 15, 2025, an additional 11,900 shares were sold at $1.31 per share.
Following these transactions, the reporting person beneficially owned 91,444 shares of Equillium common stock in direct ownership. The filing notes that the reported sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is a pre-arranged plan for trading company stock.
Equillium, Inc. (EQ) reported an insider stock sale by its Sr. Vice President and COO on a Form 4. On 11/25/2025, the officer sold 100 shares of common stock at $0.98 per share and another 7,998 shares at $0.95 per share. After these transactions, the officer beneficially owned 127,148 shares of Equillium common stock directly. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.
Equillium, Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities (common stock, preferred stock, debt, and warrants) from time to time, with terms to be set by prospectus supplements. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $75,000,000 of common stock through LifeSci Capital, included within the $250,000,000 shelf.
Under the ATM, LifeSci Capital will act as sales agent on a commercially reasonable efforts basis, and will receive up to 3.0% of gross proceeds as compensation. Proceeds to the company will be used for general corporate purposes, including research and development, working capital, and capital expenditures, as later specified in supplements.
Equillium’s common stock trades on Nasdaq as “EQ,” and the last reported sale price was $0.924 per share on November 12, 2025. Shares outstanding were 60,676,837 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Equillium, Inc. (EQ) reported a Q3 net loss of $4.23 million with $0 revenue, compared with $12.16 million in revenue a year ago tied to a now‑ended Ono arrangement. Operating expenses were $4.58 million versus $12.84 million last year, reflecting a smaller cost base post‑transition.
Cash and cash equivalents were $33.12 million and stockholders’ equity totaled $30.94 million. The company closed an August 2025 private placement for ~$30 million gross (common stock and pre‑funded warrants), and may raise up to an additional ~$20 million upon clinical and price‑based milestones. During Q3, it also sold shares via its ATM facility for ~$0.9 million gross. Shares outstanding were 60,676,837 at September 30, 2025, and 60,893,283 as of November 10, 2025.
The company terminated prior Biocon agreements and is focusing on EQ504, an aryl hydrocarbon receptor modulator, with an intended Phase 1 proof‑of‑mechanism study by mid‑2026. Management indicates existing cash is expected to fund operations through 2027.
Equillium, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into other SEC filings except as expressly specified by reference.
Equillium, Inc. filed an amended report to update its previously disclosed change in independent auditor. The company confirms that Crowe LLP has now completed its client acceptance procedures and, on October 21, 2025, executed an engagement letter to serve as Equillium’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The company states that during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and through October 21, 2025, it did not consult with Crowe on specific accounting treatments, potential audit opinions, or any issues involving disagreements or reportable events under SEC rules.
Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.
Equillium, Inc. has filed a prospectus supplement for an at-the-market offering of shares of its common stock with an aggregate offering price of up to $75,000,000 under its existing Open Market Sale Agreement with LifeSci Capital LLC.
This prospectus supplement updates and expands a prior program that had covered up to $21,950,000 of common stock. Equillium has already sold 1,719,485 shares for aggregate gross proceeds of $0.96 million under the agreement. A legal opinion from Cooley LLP on the validity of the shares is included as an exhibit.
Equillium, Inc. has filed a prospectus supplement for an at-the-market offering of shares of its common stock with an aggregate offering price of up to $75,000,000 under its existing Open Market Sale Agreement with LifeSci Capital LLC.
This prospectus supplement updates and expands a prior program that had covered up to $21,950,000 of common stock. Equillium has already sold 1,719,485 shares for aggregate gross proceeds of $0.96 million under the agreement. A legal opinion from Cooley LLP on the validity of the shares is included as an exhibit.
Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.
The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.
Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.
The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.